Роль интерлейкина-6 в синдроме ишемии-реперфузии и отторжении почечного трансплантата


Ватазин А.В., Зулькарнаев А.Б., Астахов П.В., Василенко И.А., Крстич М., Артемов Д.В.

ФУВ ГБУЗ МО МОНИКИ им. М.Ф. Владимирского, Москва; Филиал ГБОУ ВПО РНИМУ им. Н.И. Пирогова МЗ РФ “Научно-клинический центр геронтологии”, Москва
Представлено патогенетическое значение интерлейкина-6 в развитии синдрома ишемии-реперфузии и отторжении почечного трансплантата.

Литература



  1. Биленко М.В. Ишемические и реперфузионные повреждения органов: молекулярные механизмы, пути предупреждения и лечения. М.: Медицина. 1989.

  2. Kosieradzki M., Rowinski W. Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant. Proc. 2008; 40(10): 3279-3288.

  3. Alvarez-Vijande R., Luque Galvez P., Alcaraz Asensio A., Grupo de Trasplante Renal Experimental. Cell energetic loading in experimental renal transplant with different periods of warm ischemia. [Article in Spanish]. Actas. Urol. Esp. 2008; 32(1): 41-58.

  4. Гринев М.В., Гринев К.М. Цитокин-ассоциированные нарушения микроциркуляции (ишемически-реперфузионный синдром) в генезе критических состояний. Хирургия. Журнал им. Н.И. Пирогова. 2010; 12: 70-76.

  5. Хубутия М.Ш., Вагабов В.А., Темнов А.А. и др. Паракринные механизмы противовоспалительного действия при трансплантации мезенхимальных стволовых клеток. Обзор литературы. Трансплантология. 2012; 1-2: 20-27.

  6. Jang H.R., Rabb H. The innate immune response in ischemic acute kidney injury. Clin. Immunol. 2009; 130(1):41-50.

  7. Hirano T., Hirasawa H., Oda S. et al. Modulation of polymorphonuclear leukocyte apoptosis in the critically ill by removal of cytokines with continuous hemodiafiltration. Blood. Purif. 2004; 22(2): 188-197.

  8. Akahori T., Sho M., Kashizuka H. et al. A. Novel CCR5/CXCR3 antagonist protects intestinal ischemia/reperfusion injury. Transplant Proc. 2006; 38(10): 3366-3368.

  9. Camporeale A., Poli V. IL-6, IL-17 and STAT3: a holy trinity in auto­immunity? Front. Biosci. 2012; 17: 2306-2326.

  10. Pedersen B.K. Muscular interleukin-6 and its role as an energy sensor. Med. Sci. Sports. Exerc. 2012; 44(3): 392-396.

  11. Nechemia-Arbely Y., Barkan D., Pizov G. et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J. Am. Soc. Nephrol. 2008; 19(6):1106-1115.

  12. Taki-Eldin A., Zhou L., Xie H.Y. et al. Liver regeneration after liver transplantation. Eur. Surg. Res. 2012; 48(3):139-153.

  13. Chen J., Hartono J.R., John R. et al. Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int. 2011; 80(5): 504-515.

  14. Lu C.Y., Winterberg P.D., Chen J. et al. Acute kidney injury: a conspiracy of toll-like receptor 4 on endothelia., leukocytes., and tubules. Pediatr Nephrol. 2012; 27(10):1847-1854.

  15. Mihara M., Hashizume M., Yoshida H. et al. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond). 2012; 122(4): 143-159.

  16. Tanaka T., Narazaki M., Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Ann. Rev. Pharmacol. Toxicol. 2012; 52: 199-219.

  17. Betts B.C., St Angelo E.T., Kennedy M. et al. Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses. Blood. 2011; 118(19): 5340-5343.

  18. Jordan S.C., Kahwaji J., Toyoda M. et al. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr. Opin. Organ Transplant. 2011; 16(4): 416-424.

  19. Gong W., Klopfel M., Reutzel-Selke A. et al. High weight differences between donor and recipient affect early kidney graft function - a role for enhanced IL-6 signaling. Am. J. Transplant. 2009; 9(8): 1742-1751.

  20. de Vries D.K., Lindeman J.H., Tsikas D. et al. Early renal ischemia-reperfusion injury in humans is dominated by IL-6 release from the allograft. Am. J. Transplant. 2009; 9(7): 1574-1584.

  21. Kaminska D., Tyran B., Mazanowska O. et al. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation. 2007; 84(9): 1118-1124.

  22. Hosgood S.A., Hunter J.P., Nicholson M.L. Early urinary biomarkers of warm and cold ischemic injury in an experimentalkidney model. J. Surg. Res. 2012; 174(2): 85-90.

  23. Domanski L., Pawlik A., Safranow K. et al. Changes in cytokine concentrations in graft renal vein during reperfusion in patients with and without delayed graft function. Ann. Acad. Med. Stetin. 2008; 54(1): 49-52.

  24. Nowak M., Wyczalkowska-Tomasik A., Wlodarczyk Z. et al. The role of the kidney in the systemic elimination of interleukin 6, platelet-derived growth factor and transforming growth factor beta. Cytokine. 2012; 59(2): 258-263.

  25. de Vries D.K., Lindeman J.H., Ringers J. et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. Am. J. Transplant. 2011;11(5):1064-1070.

  26. Kielar M.L., John R., Bennett M. et al. Maladaptive role of IL-6 in ischemic acute renal failure. J. Am. Soc. Nephrol. 2005;16(11):3315-3325.

  27. Caban A., Budzinski G., Oczkowicz G. et al. Factors determining changes in concentrations of pro-inflammatory markers in blood serum in the initial period afterkidney transplantation from dead donor. Ann. Transplant. 2009; 14(4): 10-13.

  28. Patel N.S., Chatterjee P.K., Di Paola R. et al. Endogenous interleukin-6 enhances the renal injury., dysfunction., and inflammation caused by ischemia/ reperfusion. J. Pharmacol. Exp. Ther. 2005;312(3):1170-1178.

  29. Domanski L., Pawlik A., Safranow K. et al. Purine and cytokine concentrations in the renal vein of the allograft during reperfusion. Transplant. Proc. 2007; 39(5):1319-1322.

  30. Sadeghi M., Daniel V., Lahdou I. et al. Association of pretransplant soluble glycoprotein 130 (sgp130) plasma levels and posttransplantacute tubular necrosis in renal transplant recipients. Transplantation. 2009; 88(2): 266-271.

  31. Nakagiri T., Inoue M., Minami M. et al. Immunology mini-review: the basics of T(H)17and interleukin-6 in transplantation. Transplant Proc. 2012; 44(4): 1035-1040.

  32. Wang H., Guan Q., Lan Z. et al. Prolonged renal allograft survival by donor interleukin-6deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells. Am. J. Physiol. Renal. Physiol. 2012; 302(2): F276-283.

  33. Chen G., Mi J., Xiao MZ. et al. PDIA3 mRNA expression and IL-2, IL-4, IL-6, and CRP levels of acute kidney allograft rejection in rat. Mol. Biol. Rep. 2012;3 9(5): 5233-5238.

  34. Reinhold S.W., Straub R.H., Kruger B. et al. Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks aftertransplantation. Cytokine. 2012; 57(3): 379-388.

  35. De Serres S.A., Mfarrej B.G., Grafals M. et al. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin. J. Am. Soc. Nephrol. 2012; 7(6): 1018-1025.

  36. Dahle D.O., Mj0en G., Oqvist B. et al. Inflammation-associated graft loss in renal transplant recipients. Nephrol. Dial. Transplant. 2011; 26(11):3756-3761.

  37. De Serres S.A., Vadivel N., Mfarrej B.G. et al. Monocyte-secreted inflammatory cytokines are associated withtransplant glomerulopathy in renal allograft recipients. Transplantation. 2011; 91(5): 552-559.

  38. Shen H., Goldstein D.R. IL-6 and TNF-alpha synergistically inhibit allograft acceptance. J. Am. Soc. Nephrol. 2009; 20(5): 1032-1040.

  39. Nikolova P.N., Ivanova M.I., Mihailova S.M. et al. Cytokine gene polymorphism in kidney transplantation - impact of TGF-beta 1, TNF-alpha and IL-6 on graft outcome. Transpl. Immunol. 2008; 18(4): 344-348.

  40. Karimi M.H., Daneshmandi S., Pourfathollah A.A. et al. A study of the impact of cytokine gene polymorphism in acute rejection of renal transplant recipients. Mol. Biol. Rep. 2012;39(1):509-515.

  41. Lv R., Hu X., Bai Y. et al. Association between IL-6 -174G/Cpolymorphism and acute rejection of renal allograft: evidence from a meta-analysis. Transpl. Immunol. 2012;26(1):11-18.

  42. Garbers C., Hermanns HM., Schaper F. et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012; 23(3):5-97.

  43. Jawa R.S., Anillo S., Huntoon K. et al. Analytic review: Interleukin-6 in surgery, trauma, and critical care: part I: basic science. J. Intensive Care Med. 2011; 26(1): 3-12.

  44. Ray A., Sehgal P.B. Cytokines and their receptors: molecular mechanism ofinterleukin-6 gene repression by glucocorticoids. J. Am. Soc. Nephrol. 1992; 2(12 Suppl.) :S214-221.

  45. Кетлинский С.А. Взаимосвязь между гормонами и цитокинами в регуляции гипоталамус-гипофизарной-адреналовой оси. Медицинский академический журнал. 2008;8(1):51-60.

  46. Bayrak S., Yurekli I., Gokalp O. et al. Assessment of protective effects of methylprednisolone and pheniramine maleate on reperfusion injury in kidney after distant organ ischemia: a rat model. Ann. Vasc. Surg. 2012; 26(4):559-565.

  47. Reikeras O., Helle A., Krohn C.D. et al. Effects of high-dose corticosteroids on post-traumatic inflammatory mediators. Inflamm. Res. 2009;58(12):891-897.

  48. Jawa R.S., Anillo S., Huntoon K. et al. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J. Intensive Care Med. 2011;26(2):73-87.

  49. Seam N., Meduri GU., Wang H. et al. Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit. Care Med. 2012;40(2):495-501.

  50. Saidi R.F., Chang J., Verb S. et al. The effect of methylprednisolone on warm ischemia-reperfusion injury in the liver. Am. J. Surg. 2007;193(3):345-348.

  51. Cicora F., Roberti J., Lausada N. et al. Donor preconditioning with rabbit anti-rat thymocyte immunoglobulin amelioratesischemia reperfusion injury in rat kidney transplantation. Transpl. Immunol. 2012; 27(1): 1-7.

  52. Dittrich A., Khouri C., Sackett S.D. et al. Glucocorticoids increase interleukin- 6-dependent gene induction by interfering with the expression of the suppressor of cytokine signaling 3 feedback inhibitor. Hepatology. 2012; 55(1): 256-266.

  53. Linares Quevedo A.I., Burgos Revilla F.J., Villafruela Sanz J.J. et al. Usefulness of cytokines as surgical aggression markers in the ischemia- reperfusion syndrome and post transplant renal function in an experimental model of laparoscopic vs. open renal autotransplantation. [Article in Spanish]. Arch. Esp. Urol. 2008;61(1):41-54.

  54. Dale O., Somogyi A.A., Li Y. et al. Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematicreview and meta­analysis. Anesth. Analg. 2012;115(4):934-943.

  55. Lauzurica R., Pastor M.C., Bayes B. et al. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. Transplant. Proc. 2007;39(7): 2170-2172.


Об авторах / Для корреспонденции


Ватазин А.В. – профессор, руководитель отдела трансплантологии, нефрологии и хирургической гемокоррекции, Заслуженный деятель науки РФ, д.м.н.;
Зулькарнаев А.Б. – доцент кафедры трансплантологии, нефрологии и искусственных органов ФУВ ГБУЗ МО МОНИКИ им. М.Ф. Владимирского, к.м.н.
E-mail: 7059899@gmail.com;
Астахов П.В. – профессор, профессор кафедры трансплантологии, нефрологии и искусственных органов, д.м.н.;
Василенко И.А. – профессор, зав. лабораторией компьютерной цитоморфометрии Филиала ГБОУ ВПО РНИМУ им. Н.И.Пирогова МЗ РФ “Научно-клинический центр геронтологии”, д.м.н.;
Крстич М. – младший научный сотрудник хирургического отделения органного донорства.
Артемов Д.В. – клинический ординатор кафедры трансплантологии, нефрологии и искусственных органов.


Похожие статьи


Бионика Медиа